Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 15Nasopharyngeal Carcinoma 8Lung Neoplasms 7Uterine Cervical Neoplasms 3Melanoma 3Esophageal Squamous Cell Carcinoma 3Colorectal Neoplasms 3Nasopharyngeal Neoplasms 2Lymphoma, T-Cell 2Breast Neoplasms 2Stomach Neoplasms 1Sarcoma 1Recurrence 1Radiation Injuries 1Quality of Life 1Osteosarcoma 1Non-squamous Non-small Cell Lung Cancer 1Neuroblastoma 1Lymphoma, T-Cell, Peripheral 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Esophageal 1Carcinoma, Hepatocellular 1Bone Neoplasms 1Advanced Pancreatic Cancer 1Advanced Gastric Cancer 1Advanced Colorectal Cancer 1

Interventions

Gemcitabine 4Taxes 3S 1 (combination) 3130-nm albumin-bound paclitaxel 3toripalimab 2Drug Therapy 2Albumin-Bound Paclitaxel 2surufatinib 1nimotuzumab 1envafolimab 1endostar protein 1conteltinib 1camrelizumab 1apatinib 1Simvastatin 1Radiosurgery 1Nivolumab 1Metformin 1Immunotherapy 1Endostatins 1Digoxin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Advanced Pancreatic Cancer × endostar protein × Clear all
NCT05298020 2022-03-28

Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer

The Affiliated Hospital of Xuzhou Medical University

Phase 2 Unknown
20 enrolled
Gastrointestinal

Advanced Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡